What has been reported to occur when Ch+ red cells are transfused to a patient with anti-Ch?

When transfusing Ch+ red cells to a patient with anti-Ch, it has been reported that there is no clinically significant red cell destruction. This is due to the nature of the anti-Ch antibody, which is typically not associated with a robust hemolytic reaction. Although the antibody may bind to the Ch+ red cells, the binding does not usually trigger complement activation or significant phagocytosis by the immune system, leading to minimal or no destruction of the transfused red cells.

In instances where patients possess anti-Ch antibodies, the compatibility testing is crucial to ensure a safe transfusion outcome. In contrast, clinically significant immune red cell destruction would suggest a more aggressive immune response, which is not typically observed with anti-Ch. Additionally, decreased 51Cr red cell survivals and febrile transfusion reactions are not relevant in this specific context, as the interactions here don't lead to the complications associated with those outcomes.